Alpha-Synuclein (α-Syn)

Alpha-Synuclein (α-Syn)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Alpha-Synuclein (α-Syn)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td><a href="/genes/snca">SNCA</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P37840" target="_blank">P37840</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td><a href="https://www.rcsb.org/structure/1XQ8" target="_blank">1XQ8</a>, <a href="https://www.rcsb.org/structure/6A6B" target="_blank">6A6B</a>, <a href="https://www.rcsb.org/structure/4R0P" target="_blank">4R0P</a></td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>14 kDa (140 aa)</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Presynaptic terminals, nucleus</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Synuclein family</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td><a href="/diseases/parkinsons-disease">Parkinson's Disease</a>, <a href="/diseases/dementia-with-lewy-bodies">DLB</a>, <a href="/diseases/multiple-system-atrophy">MSA</a></td>
</tr>
</table>

Alpha-Synuclein (α-Syn)

Overview

Alpha-Synuclein (α-Syn)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Alpha-Synuclein (α-Syn)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td><a href="/genes/snca">SNCA</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P37840" target="_blank">P37840</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td><a href="https://www.rcsb.org/structure/1XQ8" target="_blank">1XQ8</a>, <a href="https://www.rcsb.org/structure/6A6B" target="_blank">6A6B</a>, <a href="https://www.rcsb.org/structure/4R0P" target="_blank">4R0P</a></td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>14 kDa (140 aa)</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Presynaptic terminals, nucleus</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Synuclein family</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td><a href="/diseases/parkinsons-disease">Parkinson's Disease</a>, <a href="/diseases/dementia-with-lewy-bodies">DLB</a>, <a href="/diseases/multiple-system-atrophy">MSA</a></td>
</tr>
</table>

Alpha-Synuclein (α-Syn)

Overview

Alpha-synuclein (α-Syn) is a 140-amino acid protein encoded by the [SNCA gene](/genes/snca) that is centrally involved in the pathogenesis of Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), collectively termed synucleinopathies [@spillantini1997]. Under pathological conditions, α-Syn misfolds, aggregates, and forms Lewy bodies and Lewy neurites, which are hallmark inclusions in the brains of patients with these disorders [@baba1998].

Alpha-synuclein is a natively unfolded protein that can adopt multiple conformational states, including α-helical structures upon membrane binding and β-sheet-rich conformations during aggregation. The propagation of α-Syn pathology follows a prion-like pattern, spreading from peripheral sites to the central nervous system and between brain regions in a stereotypic manner [@yamasaki2026].

Gene and Isoforms

SNCA Gene

The SNCA gene is located on chromosome 4q21.31 and consists of six exons. The protein is expressed primarily in neurons, particularly in presynaptic terminals, though lower expression is found in other cell types including oligodendrocytes and astrocytes. The promoter region contains binding sites for transcription factors that regulate tissue-specific expression.

Alternative Splicing

Multiple isoforms of α-Syn are generated through alternative splicing [@eliezer2001]:

• α-Syn-140: Full-length (140 aa) - predominant species in most tissues
• α-Syn-126: Exon 3 skipped (126 aa) - lacks central region, less aggregation-prone
• α-Syn-98: Exons 3 and 5 skipped (98 aa) - shortened, primarily in brain
• α-Syn-115: Alternative splice variant (115 aa) - rare isoform

Molecular Structure

Domain Architecture

Alpha-synuclein contains three distinct domains that mediate its diverse functions [@wood2006]:

N-Terminal Domain (1-60 aa)

• Amphipathic α-helical region upon membrane binding
• Contains 7 imperfect repeats of the KTKEGV motif
• Binds to acidic phospholipid membranes
• Mutation hotspots located here (A30P, E46K, H50Q, G51D, A53T)
• The repeat sequences mediate lipid binding and may facilitate vesicle clustering

• Hydrophobic NAC (Non-Aβ Component) region
• Critical for aggregation (residues 71-82, known as the "NACore")
• Forms the core of β-sheet structures in fibrils
• Highly prone to amyloid formation
• This region is protected in the fibril core and is resistant to proteolysis

• Acidic, proline-rich region
• Highly charged and flexible (15 Asp/Glu residues)
• Regulates aggregation propensity (inhibitory)
• Contains phosphorylation sites (Ser129, Ser87)
• The acidic tail may act as a "chaperone" preventing aggregation

Conformational States

Natively Unfolded
In solution at physiological pH, α-Syn exists as a natively unfolded monomer with little persistent secondary structure. This disordered state allows the protein to interact with multiple partners and adopt different conformations based on environmental conditions.

α-Helical Conformation
Upon binding to lipid membranes, α-Syn adopts an α-helical conformation, particularly in the N-terminal region [5]. This membrane-bound form may be functionally relevant for normal synaptic vesicle regulation. The helical structure spans approximately residues 1-100 and is organized as two antiparallel helices separated by a short linker.

β-Sheet Aggregation
Under pathological conditions, α-Syn converts to β-sheet-rich oligomers and fibrils [@conway2000]. This conformational transition is central to disease pathogenesis and can be seeded by pre-existing aggregates. The fibrils have a characteristic cross-β structure with strands perpendicular to the fibril axis.

Post-Translational Modifications

Pathological modifications regulate α-Syn aggregation and toxicity [@tenreiro2014]:

| Modification | Site | Effect on Pathology |
|--------------|------|---------------------|
| Phosphorylation | Ser129, Ser87, Tyr125, Tyr133 | Ser129 phosphorylation is hallmark (~90% in LB) |
| Ubiquitination | Multiple Lys residues | Degradation signals, found in LB [@martinez2003] |
| Sumoylation | Lys102, Lys96 | Alters aggregation propensity |
| Truncation | C-terminus (residues 1-120, 1-110) | Generates aggregation-prone fragments |
| Nitration | Tyr39, Tyr125, Tyr133 | Promotes aggregation, found in PD brain |
| Oxidation | Met1, Met5, Met116, Met127 | Promotes aggregation, oxidative stress marker |
| Glycation | Multiple sites | Cross-linking, advanced glycation end-products |

Phosphorylation at Ser129 is the most specific pathological modification, found in over 90% of Lewy body α-Syn. This modification is mediated by several kinases including casein kinases and PLK3, and may serve as a useful biomarker.

Normal Physiological Functions

Synaptic Vesicle Regulation

Alpha-synuclein plays important roles in synaptic function [@culla2011]:

• Regulates synaptic vesicle pools: Controls the reserve pool of synaptic vesicles
• Modulates dopamine release: Influences quantal content and release probability
• Influences vesicle trafficking: Affects vesicle endocytosis and recycling
• Participates in synaptic plasticity: Required for long-term potentiation

Membrane Binding

The N-terminal domain binds to synaptic vesicles [5]:

• Phospholipid membranes (especially acidic phospholipids)
• Synaptic vesicle clustering and organization
• May act as a molecular chaperone for membrane fusion proteins
• Fatty acid binding may regulate its function

Neuroprotection

Under normal conditions, α-Syn may provide neuroprotective functions:

• Antioxidant properties: May scavenge reactive oxygen species
• Anti-apoptotic effects: Interacts with apoptotic pathways
• Chaperone activity: Helps prevent protein aggregation
• DNA protection: Binds to DNA and may protect against damage

SNARE Complex

Alpha-synuclein interacts with the SNARE complex:

• Facilitates SNARE complex assembly
• Modulates neurotransmitter release
• Critical for synaptic function
• May regulate the size of the readily releasable pool

Metal Binding

α-Syn can bind metal ions, which may regulate its function and aggregation [@devine2011]:

• Iron: Promotes aggregation, elevated in PD brain
• Copper: Binds with high affinity, affects folding
• Calcium: May promote membrane binding

Aggregation Mechanisms

Misfolding and Oligomerization

The aggregation of α-Syn follows a nucleation-dependent mechanism:

Toxic Oligomeric Species

Soluble oligomeric intermediates are considered the primary toxic species [@cao2012]:

• Protofibrils: Larger oligomeric assemblies, can be membrane-permeable
• Annular oligomers: Pore-like structures that disrupt membranes
• Spherical oligomers: Common early intermediates
• Fibrillar oligomers: Prefibrillar aggregates on the pathway to fibrils

• Disrupt membrane integrity through pore formation
• Impair synaptic function and plasticity
• Cause mitochondrial dysfunction and energy failure [@tsika2010]
• Activate endoplasmic reticulum stress pathways [@guo2008]
• Spread between cells and seed further aggregation

Strain Diversity

Like other amyloid proteins, α-Syn can form distinct strains that correlate with clinical phenotypes [@sideris2026]:

• Parkinson's disease type: Classic Lewy body pathology
• Multiple system atrophy type: More aggressive, glial cytoplasmic inclusions (GCIs)
• Dementia with Lewy bodies type: Cortical Lewy bodies, less aggressive
• Hallmark pattern A (HBPA): Highly aggregated, protease-resistant

Cell-to-Cell Spread

Alpha-synuclein pathology propagates in a prion-like manner [2]:

• Released from affected neurons via exocytosis or extracellular vesicles
• Internalized by neighboring cells through various mechanisms (receptor-mediated, endocytosis)
• Seeds aggregation of endogenous α-Syn through templated conversion
• Spreads along neural networks following connectivity patterns

Disease Role in Parkinson's Disease

Lewy Bodies

The hallmark pathological inclusion in PD is the Lewy body [@spillantini1997]:

• Structure: Spherical cytoplasmic inclusions, 5-25 μm diameter
• Composition: Primarily fibrillar α-Syn with other proteins
• Modifications: Ubiquitinated and heavily phosphorylated at Ser129
• Cellular context: Surrounded by damaged organelles, displaced nuclei

Lewy Neurites

Abnormal neuritic processes containing α-Syn aggregates:

• Distal portions of axons are particularly affected
• Contribute to connectivity loss and circuit dysfunction
• May precede Lewy body formation in disease progression

Braak Staging

The progression of α-Syn pathology follows a predictable pattern:

• Stage 1-2: Brainstem (dorsal motor nucleus of vagus, locus coeruleus)
• Stage 3-4: Limbic system (amygdala, hippocampus, anterior olfactory nucleus)
• Stage 5-6: Neocortex (primary sensory and association areas)

Braak Hypothesis

The dual-hit hypothesis suggests:

• Entry route: Pathogen may enter via olfactory or nasal route
• First hit: Spreads to brainstem via vagus nerve
• Second hit: Later spreads to cortex
• This explains the clinical progression from non-motor to motor to cognitive symptoms

Other Synucleinopathies

Dementia with Lewy Bodies (DLB)

• Cortical Lewy bodies prominent [@baba1998]
• Fluctuating cognition with prominent attention deficits
• Visual hallucinations (often early, detailed)
• Parkinsonism (typically symmetric onset)
• Core feature: REM sleep behavior disorder (RBD)
• Rapid eye movement behavior disorder often precedes cognitive symptoms by years

Multiple System Atrophy (MSA)

• Oligodendroglial inclusions (GCIs) - distinct from Lewy bodies
• More aggressive progression than PD
• Motor symptoms (MSA-P: parkinsonian, MSA-C: cerebellar)
• Autonomic dysfunction prominent (orthostatic hypotension, urinary dysfunction)
• Poor levodopa response

Pure Autonomic Failure (PAF)

• Orthostatic hypotension as primary feature
• Peripheral α-Syn pathology primarily
• May progress to PD/DLB in some cases (approximately 20%)

REM Sleep Behavior Disorder (RBD)

• Loss of REM sleep atonia
• Dream-enacting behaviors (acting out dreams)
• Often prodrome to synucleinopathy
• High conversion rate to PD/DLB/MSA (over 80% after 10 years)
• Represents a window for neuroprotective intervention

Therapeutic Strategies

Immunotherapies

Active Immunization

• PD01A (Affiris): Peptide vaccine targeting α-Syn, showed antibody response
• ACI-35 (Affiris): Liposome-based vaccine targeting phosphorylated α-Syn
• Generates antibodies that may clear pathological protein

• Prasinezumab (PRX002, Roche): Anti-α-Syn antibody, mixed results in Phase 2
• Cinpanemab (BIIB054, Biogen): Antibody targeting oligomers, discontinued after Phase 2
• UCB-7935 (UCB): Phase 1 results showed good safety profile

Aggregation Inhibitors

• Anle253b: Dual Aβ/tau inhibitor, in development
• Curcumin derivatives: Natural compound with aggregation inhibition
• Epigallocatechin-3-gallate (EGCG): Green tea polyphenol, in trials
• Small molecules targeting the NACore: Specific aggregation blockers

Small Molecule Approaches

• Dopamine modulation: May reduce toxic species formation
• Metal chelation: Targeting iron and copper interactions
• Neurturin: GDNF analog for neuroprotection
• mTOR inhibitors: Promote autophagy of α-Syn

Gene Therapy

• AAV2-GAD: Glutamic acid decarboxylase gene
• AAV2-AADC: Aromatic L-amino acid decarboxylase
• Gene silencing: ASOs and RNAi targeting SNCA [@cheng2025]
• α-Syn reduction: Viral vector delivery of shRNA

Cell Replacement

• Cell transplantation: Fetal dopamine neurons (historical)
• iPSC-derived neurons: Patient-specific, in development
• Growth factors: GDNF, neurturin delivery
• Stem cell-derived dopamine neurons: Clinical trials ongoing

Emerging Approaches

• Protein replacement: Delivery of functional α-Syn
• Molecular chaperones: Enhance proper folding
• Autophagy enhancers: mTOR-independent pathways
• Exosome-based delivery: Cell-derived vesicles for therapy

Biomarkers

Cerebrospinal Fluid

• Total α-Syn: Decreased in PD (released from damaged neurons)
• Oligomeric α-Syn: Increased, more specific for synucleinopathy
• Phosphorylated Ser129 α-Syn: Disease-specific, most promising
• α-Syn/β-Syn ratio: Potential diagnostic utility

Blood Biomarkers

• NfL: Neurofilament light chain - general neurodegeneration marker
• p-Ser129 α-Syn: Ultra-sensitive assays now available [3]
• Total α-Syn: Variable results, affected by blood cell contamination

Imaging

• DatSCAN: Dopamine transporter imaging - shows presynaptic deficit
• MIBG imaging: Cardiac sympathetic denervation - specific for Lewy body disease
• Transcranial sonography: Substantia nigra hyperechogenicity
• PET ligands: Emerging α-Syn specific tracers in development

Seed Amplification Assays

• RT-QuIC: Real-time quaking-induced conversion - highly sensitive
• PMCA: Protein misfolding cyclic amplification
• Very sensitive for early detection, even in prodromal stages [4]
• Can detect pathology in CSF, tissue, and blood

Genetics

Mutations

Missense Mutations

• A53T: Early-onset, aggressive PD, accelerated aggregation
• A30P: Reduced membrane binding, slower aggregation
• E46K: Increased aggregation, Lewy body disease
• H50Q: Increased aggregation, progressive parkinsonism
• G51D: Early-onset, atypical features, rapid progression
• A53V: Less common, variable presentation

Gene Duplication/Triplication

• SNCA duplication: Variable penetrance, dose-dependent
• SNCA triplication: Early-onset, severe, complete penetrance
• The triplication explains that increased expression alone can cause disease

Risk Factors

• SNCA polymorphisms: Multiple risk variants identified in GWAS
• GBA: Glucocerebrosidase mutations - major risk factor
• LRRK2: Leucine-rich repeat kinase 2 - some variants increase risk
• PARKIN, PINK1, DJ-1: Mitochondrial genes - recessive parkinsonism
• MAPT: Tau gene - interacts with α-Syn pathology

Interactions

Protein Partners

| Partner | Interaction | Functional Effect |
|---------|-------------|-------------------|
| Synphilin-1 | Binding | Lewy body formation |
| Tau | Co-aggregation | Cross-seeding, combined pathology |
| Hsp70 | Chaperone | Aggregation inhibition |
| Hsp90 | Chaperone | Proteostasis regulation |
| NSF | SNARE interaction | Synaptic vesicle recycling |
| CSPα | Chaperone | Synaptic function |
| D2/D3 dopamine receptors | Binding | Modulates receptor signaling |
| Mitochondrial proteins | Various | Mitochondrial dysfunction |

Lipid Interactions

• Phosphatidylinositol, phosphatidylserine
• Fatty acids (palmitate, oleate)
• Membrane rafts

Recent Research (2025-2026)

Recent studies have advanced our understanding of α-synuclein pathology and therapeutic strategies [1-7]:

Propagation and Seeding Mechanisms

• α-Syn strains: Different strains of α-synuclein show distinct biological activities and may explain clinical variability in synucleinopathies
• Cell-to-cell transmission: New insights into the mechanisms of α-syn propagation have revealed novel therapeutic targets

Biomarker Advances

• Blood biomarkers: Ultra-sensitive assays now enable detection of α-syn pathology in blood samples, improving accessibility
• Seed amplification: RT-QuIC and PMCA technologies continue to show promise for early diagnosis

Therapeutic Developments

• Immunotherapy: Anti-α-synuclein antibodies continue in clinical trials with updated protocols
• Gene therapy: Novel delivery methods for ASO and RNAi approaches are being explored

Exosome Research

• Exosome-mediated delivery: Studies on exosome nanodelivery systems for α-syn targeting show promise
• Zombosomes: Novel anucleated cellular vehicles that spread α-syn pathology

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease) — Primary synucleinopathy
• [Lewy Body Dementia](/diseases/lewy-body-dementia) — Synucleinopathy with dementia
• [SNCA Gene](/genes/snca) — Gene encoding alpha-synuclein
• [Multiple System Atrophy](/diseases/multiple-system-atrophy) — Aggressive synucleinopathy
• [Synucleinopathies](/diseases/alpha-synucleinopathies) — Category of diseases with alpha-synuclein pathology
• [Tau Protein](/proteins/tau) — Another key protein in neurodegeneration
• [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies) — Cortical Lewy body disease

External Links

• [SNCA Gene - NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/6622) - Official gene information
• [Alpha-Synuclein - UniProt](https://www.uniprot.org/uniprotkb/P37840) - Protein sequence and structure
• [Alpha-Synuclein and Parkinson's - Nature Reviews](https://www.nature.com/articles/nrn.2016.125) - Review article
• [Michael J. Fox Foundation - Parkinson's Research](https://www.michaeljfox.org/) - Patient advocacy and research funding
• [Allen Human Brain Atlas - SNCA Expression](https://human.brain-map.org/microarray/search/show?search_term=SNCA)
• [Allen Cell Type Atlas - SNCA](https://celltypes.brain-map.org/)
• [Allen Mouse Brain Atlas - SNCA](https://mouse.brain-map.org/)
• [BrainSpan Atlas of the Developing Human Brain](https://www.brainspan.org/)

Pathway Diagram

<!-- scidex-demo:diagram:end -->

<!-- scidex-demo:links:start -->

SciDEX Links

Related Hypotheses

• [Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — score 0.78; target APOE; neurodegeneration.
• [SASP-Driven Aquaporin-4 Dysregulation](/hypothesis/h-807d7a82) — score 0.78; target AQP4; neurodegeneration.
• [SASP-Mediated Cholinergic Synapse Disruption](/hypothesis/h-1acdd55e) — score 0.76; target MMP2/MMP9; neurodegeneration.
• [Circadian Clock-Autophagy Synchronization](/hypothesis/h-b7898b79) — score 0.76; target CLOCK; neurodegeneration.

Related Analyses

• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analyses/SDA-2026-04-01-gap-008)
• [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analyses/SDA-2026-04-01-gap-009)
• [APOE4 structural biology and therapeutic targeting strategies](/analyses/SDA-2026-04-01-gap-010)